Methods for interpreting change over time in patient-reported outcome measures
Authors:
- the Industry Advisory Committee of International Society for Quality of Life Research (ISOQOL)T(the Industry Advisory Committee of International Society for Quality of Life Research (ISOQOL)
- K. W. WyrwichKWK. W. Wyrwich
- 17 April 2012
- journal article
- research article
- Published by Springer Nature in Quality of Life Research
- Vol. 22 (3) , 475-483
Abstract
Interpretation guidelines are needed for patient-reported outcome (PRO) measures’ change scores to evaluate efficacy of an intervention and to communicate PRO results to regulators, patients, physicians, and providers. The 2009 Food and Drug Administration (FDA) Guidance for Industry Patient-Reported Outcomes (PRO) Measures: Use in Medical Product Development to Support Labeling Claims (hereafter referred to as the final FDA PRO Guidance) provides some recommendations for the interpretation of change in PRO scores as evidence of treatment efficacy. This article reviews the evolution of the methods and the terminology used to describe and aid in the communication of meaningful PRO change score thresholds. Anchor- and distribution-based methods have played important roles, and the FDA has recently stressed the importance of cross-sectional patient global assessments of concept as anchor-based methods for estimation of the responder definition, which describes an individual-level treatment benefit. The final FDA PRO Guidance proposes the cumulative distribution function (CDF) of responses as a useful method to depict the effect of treatments across the study population. While CDFs serve an important role, they should not be a replacement for the careful investigation of a PRO’s relevant responder definition using anchor-based methods and providing stakeholders with a relevant threshold for the interpretation of change over time.Keywords
This publication has 49 references indexed in Scilit:
- Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction QuestionnaireInternational Clinical Psychopharmacology, 2009
- Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two yearsBMC Neurology, 2008
- The Clinical Significance of Quality-of-Life Results: Practical Considerations for Specific AudiencesMayo Clinic Proceedings, 2002
- Assessing Meaningful Change in Quality of Life Over Time: A Users' Guide for CliniciansMayo Clinic Proceedings, 2002
- Group vs Individual Approaches to Understanding the Clinical Significance of Differences or Changes in Quality of LifeMayo Clinic Proceedings, 2002
- Methods to Explain the Clinical Significance of Health Status MeasuresMayo Clinic Proceedings, 2002
- The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A reviewJournal of Clinical Epidemiology, 1992
- Measurement of health statusControlled Clinical Trials, 1989
- Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitationArchives of internal medicine (1960), 1988
- A controlled trial of digoxin in congestive heart failureThe American Journal of Cardiology, 1988